Patient survival is shorter with increasing number of adverse lesions, regardless of the presence of hyperdiploidy. (A) Venn diagram to show that within the subset of patients with hyperdiploidy, there is cosegregation of additional adverse cytogenetic lesions. (B) Kaplan-Meier survival curves within the group of patients with hyperdiploidy predicted shorter OS with the coexistence of each adverse lesion alone independently and even shorter OS when >1 adverse lesion was present. *Pairwise comparisons were established for median OS values for HRD alone (60.9 months) vs HRD plus adverse translocation alone (40.1 months; log-rank P = .180), HRD plus del17p alone (35.2 months; log-rank P = .003), HRD plus 1q+ alone (38.1 months; log-rank P < .001), and HRD plus >1 adverse lesion (19.9 months; log-rank P < .001). NA, not applicable. (C-D) The coexistence of hyperdiploidy did not alter the PFS or OS of patients with the presence of any adverse cytogenetic lesion. Median PFS values: adverse lesion alone, 14.5 months (n = 214); adverse lesion plus hyperdiploidy, 15.4 months (n = 195). Median OS values: adverse lesion alone, 33.6 months; adverse lesion plus hyperdiploidy, 35.7 months. Log-rank P values were not significant. HRD, hyperdiploidy; NS, not significant.